Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Linezolid,Amoxicillin Trihydrate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT/AMS Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Linezolid,Amoxicillin Trihydrate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT/AMS Laboratory
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linezolid,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Persica’s PP353 Phase 1b Shows Promise for Chronic Low Back Pain
Details : PP353 is an antibiotic formulation designed for intradiscal injection under image guidance. It is being evaluated for the treatment of chronic lower back pain.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : Linezolid,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linezolid,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Persica Pharmaceuticals Completes Recruitment for Chronic Pain Trial
Details : PP353 is an antibiotic formulation for intradiscal injection, under evaluation for chronic lower back pain treatment by delivering targeted antibiotic exposure.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Linezolid,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TBAJ-876,Linezolid,Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Australian Government
Deal Size : $11.0 million
Deal Type : Funding
Australian Government Grants TB Alliance for Drug-Resistant TB Research
Details : Funding supports the NC-009 Pan-Phase 2 trial of TBAJ-876 combined with pretomanid and linezolid for treating drug-sensitive and resistant tuberculosis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 24, 2024
Lead Product(s) : TBAJ-876,Linezolid,Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Australian Government
Deal Size : $11.0 million
Deal Type : Funding
Lead Product(s) : Isoniazid,Rifampicin,Bedaquiline,Pretomanid,Linezolid,TBI-223,Sutezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : TB Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : Isoniazid,Rifampicin,Bedaquiline,Pretomanid,Linezolid,TBI-223,Sutezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : TB Alliance
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TBAJ-876,Linezolid,Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
Details : TBAJ-876 is a diarylquinoline antibiotic that targets a key enzyme of TB bacteria involved in energy production, it is being evaluated in combination with pretomanid and linezolid, for the treatment for both drug-sensitive and drug-resistant TB.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2023
Lead Product(s) : TBAJ-876,Linezolid,Pretomanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 9MW1411,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 21, 2022
Lead Product(s) : 9MW1411,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PP353 is a sustained release formulation of an antibiotic to treat the chronic disc infection, which is designed for intradiscal injection under image guidance.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2021
Lead Product(s) : Imipenem,Cilastatin,Relebactam,Vancomycin Hydrochloride,Daptomycin,Linezolid
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 30, 2021
Lead Product(s) : Imipenem,Cilastatin,Relebactam,Vancomycin Hydrochloride,Daptomycin,Linezolid
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership
TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB
Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 09, 2021
Lead Product(s) : Pretomanid,Bedaquiline,Linezolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Partnership